1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. Raf
  4. Raf Isoform

Raf

 

Raf Related Products (39):

Cat. No. Product Name Effect Purity
  • HY-15605
    Encorafenib
    Inhibitor 99.63%
    Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).
  • HY-15246
    Tovorafenib
    Inhibitor 99.89%
    Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of pan-Raf kinase.
  • HY-15767
    TAK-632
    Inhibitor 98.46%
    TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.
  • HY-10248
    RAF265
    Inhibitor 99.90%
    RAF265 is a potent RAF/VEGFR2 inhibitor.
  • HY-101963
    AD80
    Inhibitor 99.85%
    AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
  • HY-114491
    Rineterkib
    Inhibitor 99.21%
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.
  • HY-10201S
    Sorafenib-d3
    Inhibitor 99.57%
    Sorafenib-d3 (Bay 43-9006-d3) is the deuterium labeled Sorafenib.
  • HY-P1039A
    R18 TFA
    98.35%
    R18 TFA is a peptide antagonists of 14-3-3, with a KD of 70-90 nM.
  • HY-123673
    MCP110
    Inhibitor 99.82%
    MCP110 is an inhibitor of Ras/Raf-1 interaction.
  • HY-147268
    Exarafenib
    Inhibitor 99.67%
    Exarafenib (RAF/KIN_2787) is a potent, orally active pan-RAF inhibitor.
  • HY-138294
    RAS/RAS-RAF-IN-1
    Inhibitor 98.41%
    RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor.
  • HY-136567
    TBAP-001
    Inhibitor 99.85%
    TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay.
  • HY-109574
    Raf inhibitor 2
    Inhibitor 98.14%
    Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1.
  • HY-107415
    PLX7922
    Inhibitor 98.00%
    PLX7922, a RAF inhibitor, can bind with BRAFV600E.
  • HY-114491A
    Rineterkib hydrochloride
    Inhibitor 99.76%
    Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.
  • HY-109080A
    Belvarafenib TFA
    Inhibitor ≥99.0%
    Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
  • HY-N10503
    Norartocarpetin
    98.92%
    Norartocarpetin is a tyrosinase inhibitor.
  • HY-P1039
    R18
    R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM.
  • HY-117737A
    RRD-251
    Inhibitor 99.94%
    RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities.
  • HY-142452
    Pan-RAF kinase inhibitor 1
    Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase.